Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Evazarsen in uncontrolled hypertension
NCT04083222Phase 2Completed
- Sponsor
- Ionis Pharmaceuticals
- Start
- Nov 2019
- Primary completion
- Jul 2020
- Modality
- Small Interfering RNA (siRNA), Modified DNA Oligonucleotides, Single-strand DNA
- Countries
- 1
01
Overview
A Phase 2 trial of evazarsen in hypertension (HTN), sponsored by Ionis Pharmaceuticals. Started Nov 2019; status: completed.
02
Drugs
evazarsen
03
Conditions
hypertension (HTN)
Beyond the preview
Go deeper on NCT04083222.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04083222.